Trial · NCT02820519
Tolerability and Analgesic Efficacy of Loxapine in Patients With Refractory, Chemotherapy-induced Neuropathic Pain
NCT02820519, Phase 2, Terminated, University of Witten/Herdecke
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tolerability and Analgesic Efficacy of Loxapine in Patients With Refractory, Chemotherapy-induced Neuropathic Pain. Trials, record NCT02820519. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02820519
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tolerability and Analgesic Efficacy of Loxapine in Patients With Refractory, Chemotherapy-induced Neuropathic Pain
- NCT number
- NCT02820519
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- University of Witten/Herdecke
- Conditions
- Neuropathic Pain
- Interventions
- Loxapine
- First posted
- 2016-07-01
- Last updated
- 2022-07-01
- Other registries' IDs
- eudract:2014-005440-17
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Loxapine dosage with the lowest incidence of events. | After each of the four 14 days study episodes (Day 15, Day 29, Day 43, Day 57) | The primary endpoint is defined as the first occurrence of a (serious) adverse event ((S)AE) leading to dose reduction or withdrawal of loxapine ("event"). The loxapine dosage with the lowest incidence of events will be identified. |
| Secondary | Number, type, and severity of (serious) adverse events ((S)AEs) | After each of the four 14 days study episodes (Day 15, Day 29, Day 43, Day 57) | Number, type, and severity of (serious) adverse events ((S)AEs) |
| Secondary | Cumulative incidence rates for (S)AE pattern of study participants | After each of the four 14 days study episodes (Day 15, Day 29, Day 43, Day 57) | Cumulative incidence rates for (S)AE pattern of study participants |
| Secondary | Individual (study participant-related) incidence of individual (S)AEs | After each of the four 14 days study episodes (Day 15, Day 29, Day 43, Day 57) | Individual (study participant-related) incidence of individual (S)AEs |
| Secondary | Individual (study participant-related) changes in pain severity (NRS scale) | After each of the four 14 days study episodes (Day 15, Day 29, Day 43, Day 57) | Individual (study participant-related) changes in pain severity (measured by using 11-point numeric pain rating scale) in relation to treatment phase and loxapine dosage |
| Secondary | Association between event pattern and individual pain level (NRS scale) | After each of the four 14 days study episodes (Day 15, Day 29, Day 43, Day 57) | Assessment of the association between the pattern of events (Primary endpoint) related to the individual pain level (clinically relevant pain reduction is defined by an at least 30% decrease or an absolute decrease of two scale units compared to baseline using 11-point numeric pain rating scale. |
| Secondary | Individual (study participant-related) changes in pain severity (painDETECT) | After each of the four 14 days study episodes (Day 15, Day 29, Day 43, Day 57) | Individual (study participant-related) changes in pain severity (measured by painDETECT questionnaire) in relation to treatment phase and loxapine dosage |
| Secondary | Association between event pattern and individual pain level (painDETECT) | After each of the four 14 days study episodes (Day 15, Day 29, Day 43, Day 57) | Assessment of the association between the pattern of events (Primary endpoint) related to the individual changes in pain severity / characteristics measured by painDETECT questionnaire |
| Secondary | Individual (study participant-related) changes in QoL (SF-12v2) | After each of the four 14 days study episodes (Day 15, Day 29, Day 43, Day 57) | Individual (study participant-related) changes in the quality of life (12-item Short Form Health Survey (SF-12v2)) in relation to treatment phase and loxapine dosage |
| Secondary | Association between event pattern and QoL (SF-12v2) | After each of the four 14 days study episodes (Day 15, Day 29, Day 43, Day 57) | Assessment of the association between the pattern of events (Primary endpoint) related to the individual quality of life changes changes (12-item Short Form Health Survey (SF-12v2)) |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 31402867 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02820519
GET https://conductscience.org/api/trials/v1/NCT02820519/registered